Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 23, 2015 8:31 AM ET


Company Overview of miRagen Therapeutics, Inc.

Company Overview

miRagen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of microRNA (miRNA)-targeting therapies to improve human health in disease areas of high unmet medical need. It offers miR-208, a heart-specific miRNA that protects the stressed heart from maladaptive changes and preserves cardiac function; and miR-15/195 inhibitors to reduce heart muscle cell death and promote heart muscle cell regeneration following myocardial infarction or heart attack. The company also provides miR-145, a regulator of vascular smooth muscle cells, which focuses on application in hypertension and other vascular diseases to reduce pathological vascular remodeling and lower blo...

6200 Lookout Road

Suite 100

Boulder, CO 80301

United States

Founded in 2006





Key Executives for miRagen Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Chairman of The Board
Age: 40
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Member of the Scientific Advisory Board
Age: 69
Co-Founder and Director
Age: 74
Compensation as of Fiscal Year 2014.

miRagen Therapeutics, Inc. Key Developments

Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs for Cardiovascular Disease

Servier, and miRagen Therapeutics, Inc. announced that they have extended their research collaboration by two years to October 2016 to discover, develop, and commercialize drugs targeting microRNAs for cardiovascular disease. miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNAs, including miR-208 and miR-15. Servier will lead the global clinical development and commercialization of microRNA therapeutic product candidates developed through the collaboration in all countries except the U.S. and Japan, where miRagen has retained all rights.

miRagen Therapeutics, Inc. Appoints David Rodman as Executive Vice President of Research and Development

miRagen Therapeutics, Inc. announced the appointment of David Rodman, M.D. to the position of Executive Vice President of Research and Development. Dr. Rodman is an accomplished industry veteran who brings significant translational medicine and clinical development experience to the company's executive leadership team. Prior to joining miRagen, Dr. Rodman was a Vice President of Clinical Development at Vertex Pharmaceuticals Incorporated, and before that he was Executive Director, Respiratory Translational Medicine at the Novartis Institutes for Biomedical Research.

miRagen Therapeutics, Inc. Announces Executive Appointments

miRagen Therapeutics, Inc. announced the appointments of Christopher J. Morl, M.B.A., B.Sc. (Hons), as Chief Business Officer and Aimee L. Jackson, Ph.D., as Director of Target Development. Mr. Morl and Dr. Jackson are biotech and pharmaceutical industry veterans and bring significant strategic and technical experience to the company's senior leadership team. Prior to joining miRagen, Mr. Morl worked as a consultant advising pre-clinical and clinical stage biotech companies on corporate strategy, business development and financing. He serves as a Director of the Board of Alethia Biotherapeutics Inc., where he is also Chairman of the Audit Committee. After receiving her Ph.D. from the University of Colorado Health Science Center and completing her post-doctoral training, Dr. Jackson joined Rosetta Inpharmatics/Merck in Seattle, where her team established the use of expression profiling technologies combined with RNAi for target identification, target validation, elucidation of drug mechanism-of-action, and patient stratification.

Similar Private Companies By Industry

Company Name Region
Evolus, Inc. United States
Percipio Biotherapeutics, Inc. United States
Genetic Medisyn Corp. United States
Dabs Advanced Biotech Solutions LLC United States
Hygeia Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
February 3, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact miRagen Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at